WCRG Global Research WORLD COMET RESEARCH GROUP

International Journal of Modern Innovations and Emerging Trends
Vol. 5, No. 2, 2022
Doi: 10.67228/30715628/IJMIET-2022PII8D1M
PP. 01-14

Original Article

The Future of Nano-Robotics in Medical Applications

Dr. Rakesh Chandra

Associate Professor, University of Calcutta, India.

Received: 10-03-2022 Revised: 10-25-2022 Accepted: 11-02-2022 Published: 11-04-2022

ABSTRACT

Nanorobotics is one of the most radical advances of recent medicine, which can allow making new diagnosis, treatment, and prevention of diseases more accurate than ever before. As a field involving the design and deployment of nanoscale constructs to sense, actuate, compute and intervene into biological systems, medical nanorobots can fundamentally transform the system of healthcare through enabling highly efficient, patient specific and minimally invasive therapies. The current paper is a forward looking analysis of the future of nanorobotics in the medical field based on technological building blocks, research ongoing, clinical opportunity, and major challenges which were not resolved as of today. This introduction to the abstract is the limitations of traditional medical interventions that comprise systemic drug toxicity, invasive surgical procedures, delayed diagnostics and poor specificity of treatment. Nanorobots, that are of the same size scale as biological molecules like proteins, DNA and viruses, provide a paradigm shift since they are able to interact with cell and molecular processes in real time. Such systems combine technologies in the fields of nanotechnology, materials science, micro-electromechanical systems (MEMS), artificial intelligence, and biomedical engineering to bring to fruition applications like targeted drug delivery, precision surgery on individual cells, automated disease surveillance, and regenerative medicine. A review of the development of medical nanorobotics has been given with the theoretical models of nanorobotics, experimental prototypes such as DNA-based nanorobots, magnetically actuated nanomachines, and bio-hybrid systems actuated by living cells. The suggested design provides a type of a modular nanorobot design that includes sensing, control, propulsion, and therapeutic modules with external imaging and control systems. Nanoparticle navigation, drug release and swarm coordination mathematical models are also addressed. Moreover, the experimental and simulated findings presented in the current literature are also compared and assessed on the basis of performance indicators, including targeting accuracy, biocompatibility, therapeutic efficacy, and safety. Critical analysis is made on ethical and regulatory issues as well as translation issues such as immune response, large-scale production, and clinical validation. The paper finds the conclusion that even though important issues still exist, with further interdisciplinary studies and regulation harmonization, nanorobotics might become the foundation of next-generation precision medicine.

KEYWORDS

Nanorobotics, Medical Nanotechnology, Targeted Drug Delivery, Precision Medicine, Bio-Hybrid Systems, Nanomedicine, Autonomous Therapeutic Systems.

ISSN: 3071-5628
PP: 01-14.

1. INTRODUCTION

1.1. Background

The recent developments in pharmaceuticals, diagnostic radiographies, minimally invasive surgery methods, and biotechnology have resulted in unprecedented growth in the field of modern medicine with respect to disease management and survival rate of the patients. Nevertheless, regardless of these successes, a large number of traditional medical interventions are still limited in their essence. When the diffusion pattern of a drug is non-specific, there are high chances that the drug will act on diseased and normal tissues causing a high level of systemic toxicity and serious side effects. Also, late diagnosis of disease and use of invasive diagnostic and curative treatment raise the risk of patients, lengthening the recovery process, and healthcare expenditures. These difficulties are particularly acute in complicated cases like cancer, neurological syndromes, heart and cardiovascular conditions, as well as infectious diseases when it is of utmost importance to be precise, act early, and deliver the local treatment. The field of nanorobotics has also become an incredibly promising solution to all these shortcomings by allowing medical operations to be conducted at the nanoscale, which is where the majority of the biological processes start and are controlled. Nanorobots are engineered products that require a range of 1 to 1000 nanometers in diameter, which functions in the human body to perform very specific medical duties, such as delivering drugs in precise spots, diagnosing in situ, repairing tissue, and microsurgery. They are ultra-small in size, therefore, they are able to navigate through the circulatory system, go across biological barriers, deep tissues and connect to cells, proteins and nucleic acids directly. Working on such a foundation of biology, nanorobots provide unprecedented precision and controllability here, new opportunities come up as this would enable the detection of illness in its early stages, tailored therapy, and a minimally invasive course of treatment capable of radically changing the future of health care.

1.2. Evolution of Nanorobotics in Medicine

The concept of medical nanorobots may be linked to the foresighted lecture by Richard Feynman entitled There is Passage at Bottom, in which he suggested that anything was possible at the atomic and molecular level of matter manipulation. It was further developed and popularized by Eric Drexler who introduced the idea of molecular machines which could handle complex tasks inside the body of a human being. These concepts were mostly theoretical over several years owing to the extreme constraints in nanofabrication, effective control mechanisms as well as the need to have biocompatible materials. But with the accelerated development of nanotechnology, molecular self-assembly methodologies, the development of superior materials science and biotechnology, nanorobotics has become a demonstrably possible, and increasingly viable, field of experiment. Nowadays, scientific attention is directed towards changing these ideas into practical medicine.

ISSN: 3071-5628
PP: 01-14.



Fig 1 - Evolution of Nanorobotics in Medicine

1.2.1. Targeted Drug Delivery

Targeted drug delivery is one of the most sophisticated and developed fields of medical nanorobotics application. Nano-robots can be designed to deliver therapeutic agents inside the diseased tissues sparing healthy cells. These systems would allow drug localization and will effectively increase fighting capability by responding to certain biochemical signals or external guidance fields which will help minimize systemic toxicity relative to traditional modes of drug administration.

1.2.2. Cancer Detection and Therapy

Nanorobots provide strong options of early cancer diagnosis and targeted treatment. They are able to detect disease-specific biomarkers, elevated or reduced pH levels or disease-associated enzymatic action of diseased cells. Once recognised, nanorobots could deliver the chemotherapeutic drug, achieve localised hyperthermia, or induce mechanical cell damage to the cancer cells, which causes enhanced tumor regression with the least amount of trauma to adjacent healthy tissue.

1.2.3. Thrombus Removal

Nanorobots are studied in the field of cardiovascular medicine to detect and remove blood clots (thrombi). Such nanodevices are able to go through blood vessels, detect clot formations, and trigger clot-destroying agents or mechanical destruction of thrombi. This is a specific treatment that lowers the chances of heart attack and stroke as well as bleeding complications related to systemic thrombolytic treatment.

1.2.4. Gene Editing and Delivery

Gene editing and gene delivery are other areas of high potential of nanorobotic systems. Nanorobots can be used to accomplish genetic modification with high efficiency because genetic material, including DNA, RNA, or components of a CRISPR-Cas, can be delivered to the desired target cell precisely with the aid of nanorobots. This mode has a potential to cure genetic disorders, cancers and viral infections and minimise off-target effects.

ISSN: 3071-5628
PP: 01-14.

1.2.5. Tissue Repair and Regeneration

Nanorobots can also help solve the problem of tissue repair and regeneration in regeneration medicine by supplying damaged tissue with growth factor, stem cells, or bioactive molecules. They can also assist in the elimination of cellular debris, cell proliferation and movement towards microscopic reconstruction of tissues. These abilities create new avenues in the recovery of trauma, mending internal organs, and recovery of normal physiological performance.

1.3. Future of Nano-Robotics in Medical Applications

The future of nano-robotics in the field of medicine holds the potential to transform healthcare to a new form by allowing a degree of precision, personalization, and minimal invasiveness of treatment that has never existed before. With new nanofabrication, materials science and molecular self-assembly technologies underway, nanorobots will become smaller, more dependable, and more functionally versatile. Such advancements will enable nanorobotic systems to be able to accomplish complicated tasks like real-time monitoring in the body, early clinical manifestations of diseases at the cellular level, and automatic therapeutic intervention of the diseases prior to their clinical manifestation. This may change the face of healthcare to a more proactive and preventative paradigm rather than a reactive paradigm. Artificial intelligence and machine learning will be incorporated to increase the functions of medical nanorobots. Adaptive control algorithms will be intelligent, be able to learn and adapt based on the biological environment and be able to coordinate swarm behavior to perform large-scale therapeutic tasks. This will come from raw use especially in the complex and heterogeneous ailments like cancer where nanorobot swarms could dynamically modify the treatment options with real time feedback. Further, the development of bio-hybrid systems that have been made by replacing synthetic nanostructures with living cells can enhance propulsion, sensing and biocompatibility leading to more efficient movement in the human body. Clinically, the future applications of nanorobotics can not only be limited to therapy but also precise surgery, regenerative medicine, and neural interfaces. Naughty robots may help in reconstructing damaged tissues, organ repair, or even control neural activity to treat neurological disorders. This future is however attainable with significant challenges being the safety, mass production, power delivery and the long term grand monitoring. Ethics are also significant, and to create common regulatory frameworks to make the use responsible. Through long-term, interdisciplinary study and work, nano-robotics can be a foundation technology in the medical care of the next generation, which is essentially a change in the way it is diagnosed, treated, and the outcome of patients.

2. LITERATURE SURVEY

2.1. Early Conceptual Models

Initial investigations into nanorobotics were mainly theoretical in nature seeking to prove the extreme possibility of building and making nano-scale machines. K. The notion of molecular assemblers, introduced by Eric Drexler, has suggested the possibility of programmable machines (which can convert data precisely onto a substrate in order to construct large structures) out of single atoms and molecules. These concepts were subsequently furthered by Robert A. Freitas Jr. who proposed detailed specifications of medical nanorobots including respirocytes and microbivores which are imagined to be used in the human body in diagnostics, targeted therapy and microsurgery. Though these conceptual models offered an insightful model and pointed at the transformative capability of nanorobots in medicine, they were, to a great extent, based on slender assumptions concerning material toughness, energy provision, and control systems. Their implementation was not yet realized (as they have not yet been developed with advanced nanofabrication, steady power sources and selectable actuation methods) and these models were rather long-term research roadmaps instead of deployable technologies.

2.2. Nanoparticle-Based Drug Delivery Systems

The initial viable applications of medical nanorobotics to materialise saw the light of day in drug delivery systems that used nanoparticles as substitutes, an innovation that facilitated the link between theory and practice. Liposomes, dendrimers, polymeric nanoparticles, as well as solid lipid nanoparticles were designed in order to entrap therapeutic molecules and target them specifically to diseased tissues. The exploitation of these systems was the increased permeable and retentive (EPR) effect, which allowed a concentration of nanoparticles in tumor tissues under the effects of leaky vasculature and poor lymphatic drainage. Although these carriers did not have autonomy in decision making and active navigation, they showed great enhancement in the bioavailability of drugs, lower systemic toxicity, and controlled release kinetic. Consequently, the nanoparticle drug delivery systems are frequently viewed as predecessors of the actual nanorobots, delivering meaningful lessons of biocompatibility, circulation dynamics and nanoscale interactions in biological surroundings.

2.3. DNA and Bio-Hybrid Nanorobots

New contributions in the domain of molecular biology and nanotechnology have made it possible to create even more complex nanorobotic systems, especially DNA-based and bio-hybrid nanorobots. The precise bending of DNA strands into programmable 3D structures that can execute logical operations can be achieved using DNA origami techniques. The DNA nanorobots have the ability to stay closed while circulating and specifically to open in response to molecular cues (i.e. the presence of the disease-associated proteins) and release therapeutic payloads to specific locations. Meanwhile, bio-hybrid nanorobots combine the biological units like bacteria, sperm cells, or immune cells as motors and sensors to propel and sense. These operating systems take advantage of natural motility, chemotaxis, and biocompatibility of living organisms, whereas external fields or artificial surfaces provide guidance and integration control. These strategies will be an important advancement to autonomous intelligent nanorobots of precision medicine.

2.4. Control, Imaging, and Swarm Intelligence

And the main research issue is to be able to control and track nanorobots in complex biological systems. Real-time monitoring and localization of nanorobots in vivo have been examined in advanced imaging modalities, including magnetic resonance imaging (MRI), ultrasound, optical fluorescence, and photoacoustic imaging. External actuation and navigation is typically done with the use of magnetic and acoustic fields, which can be used to provide reasonable space accuracy even

ISSN: 3071-5628
PP: 01-14.

with non-invasive control. Also inspired by biological swarms, swarm intelligence algorithms have been adopted in which high-population swarms of simple nanorobots are used to execute complex tasks involving targeted delivery of drugs or swarm-based sensing. These decentralized control approaches increase strength, scale, and tolerance to faults and swarm-based nanorobotic systems are especially appealing to clinical and therapeutic uses in the future.

3. METHODOLOGY

3.1. Proposed Nanorobot System Architecture



Fig 2 - Proposed Nanorobot System Architecture

3.1.1. Sensing Module

The sensing subunit is in charge of sensing certain biological and chemical signals of the physiological environment. It is developed to detect disease-associated biomarkers, e.g., an abnormal pH level, overexpressed enzymes, target-specific proteins occurrence in case of cancer or inflammation. The sensing module allows the high selectivity and sensitivity to the molecule with the help of functionalized nanosensors, aptamers, or antibody-based receptors. That is a real-time detection capability which permits the nanorobot to discriminate healthy tissues and pathological ones, thus activating the nanorobot at the target site only.

3.1.2. Control Module

The control module plays the role of decision-making center of the nanorobot since it interprets signals obtained in the sensing module and identifies the right response. It uses fixed logic gates, molecular networks, or externally controlled algorithms to assess the therapeutic conditions. According to this analysis, the control module regulates the navigation, activation, and drug release. Computational resources on this scale are small but simplified bio-inspired or rule-based control of the device can allow an autonomous or semi-autonomous operation to increase the precision of the treatment and reduce any unwanted interactions.

3.1.3. Propulsion Module

The propulsion module allows direct movement of the nanorobot through complicated biological fluids like blood or through interstitial spaces. Propulsion can be accomplished using magnetic actuation by an external field depending on the design, a chemical reaction based propulsion, or bio-hybrid systems based on the natural motion of bacteria or sperm cells. It is also in this mileage that localization and treatment can effectively be applied with high efficiency and drive a closer penetration of diseased tissues not penetrated by other systems, thus increasing localization efficiency and therapeutic efficacy.

3.1.4. Therapeutic Module

The therapeutic module functions in carrying and releasing and protecting the drug payload at the target site. Drugs can be contained in nanocapsules, polymer matrix or DNA-based structures to eliminate premature degradation and systemic toxicity. The therapeutic agents are delivered and released in a specific and timely way by means of controlled release mechanisms, which are activated by either internal, i.e., sensing and control module-generated signals, or external, i.e., magnetic fields or light. This controlled release is effective to increase the treatment effect and minimize the side effects as compared to the usual form of therapy.

3.2. Navigation and Control Model

Tracing and controlling the proposed nanorobot in the blood are simulated through Langevin dynamics framework, a good model to describe the motion at the micro and nanoscale where viscous forces and random thermal forces become more important than the inertial force. Mass of the nanorobot and derivative of the velocity of the nanorobot multiplied together in this model is the inertial term, which is the rate at which the velocity of the nanorobot varies with time. The counteracting force is the force of viscous drag that is proportional to the velocity of the nanorobot, and resists in the opposite direction. The size, shape and surface characteristics of the nanorobot, together with the viscosity of blood, are some of the factors involved in determining the proportionality constant, which is the viscous drag coefficient. This force of drag dominates at nanoscale and far restricts acceleration and maximum speed attainable. The model also has an externally provided magnetic force besides drag and this is the main propulsion and steering mechanism that is controlled. This magnetic force is developed when the nanorobot holds some magnetic materials or magnetizing which reacts on spatially diversified magnetic-fields external the body. Clinicians can also control nanorobots by using a combination of well-controlled strength and gradient of these fields to steer them through the desired pathways, opposing blood movement, and causing the nanorobots to navigate to a given target area like tumour or region of inflammation. Langevin model also takes action of the Brownian forces which are random collisions between the nanorobot and the molecules of surrounding blood. These are random forces that make the nanorobot move erratically as it moves towards a given direction, producing minor, inconvenient swerfs in its direction. Although Brownian motion may make the prediction of the precision in navigation less accurate, its presence in the control model allows realistic simulation and a strong-controlled design. By and large the Langevin based model of navigation and control offers a complete mathematical understanding of how nanorobots behave in a blood flow environment, which can be used to develop effective guidance protocols in order to facilitate consistent therapeutic robotics related interventions.

ISSN: 3071-5628
PP: 01-14.

3.3. Drug Release Kinetics

The proposed nanorobot controlled drug release is modeled based on the first-order release kinetics, which is a commonly used methodology to describe the process of diffusion and degradation of drugs at the nanoscale. In this model, a change in the concentration of the drug concerning time is directly proportional to the amount of the drug remaining in the nanorobot. Simply put, it implies that when the drug concentration within the nanorobot is high, the highest release rate is observed whereas when the drug is depleted rate significantly reduces. The factor of proportionality that controls this phenomenon is called release constant which demonstrates physicochemical characteristics of drug, carrier material and biological environment. Drug concentration is the quantity of therapeutic agent present to be released at any particular moment and that could be at the target site or within the nanorobot itself. The rate into which the drug is discharged by the nanorobot is determined by the release constant and is affected by the polymer degradation rate, pore size, membrane permeability, and various environmental factors including pH and temperature. The choice of the material and the design of the structure enables the nanorobot to be programmed to release the pertinent drug quickly, used in acute treatment, or to release it slowly and deliver chronic treatment. First-order kinetics is mostly suitable in nanorobotic drug delivery since the release profile is predictable and smooth minimizing phenomenal peaks of drug levels that well might result in toxicity. Besides, this model can be combined with sensing and control modules, which will permit stimulus responsive release, such that the effective release constant varies with local biochemical signals. Consequently, the drug is targeted specifically at the pathological location with the beneficial effects of increasing treatment efficacy and decreasing systemic exposure. Comprehensively, first-order drug release kinetics would offer a strong system of mathematical facilities with efficient, safe, and accurate nanorobot-based drug delivery frameworks.

3.4. Operational Flow

3.4.1. Injection into Bloodstream

The controlled nanorobots are injected into the blood of a patient via normal intravenous injection into the body, thus commencing the operational procedure. To make sure that the nanorobots would be safe in circulation without causing adverse immune response, they are made of biocompatible and non-immunogenic materials. After its introduction, they become evenly distributed throughout the vascular system and carried off by the natural flow of blood, to different body parts.

3.4.2. External Guidance and Navigation

The nanorobots are directed to the target site after injection through the application of external guiding mechanisms like magnetic fields or sound signals. The effects of blood flow and random Brownian motion are overcome with the use of these external controls, which allow selective passage through complex vascular networks. Monitoring the position of nanorobot trajectories and giving a feedback to the guidance parameters can be performed in parallel using real-time imaging techniques.

ISSN: 3071-5628
PP: 01-14.



Fig 3 - Operational Flow

3.4.3. Biomarker Detection

As nanorobots are spread in the body, the sensing modules are being used to continuously measure the local biochemical homeostasis of disease-related biomarkers in the form of abnormal pH levels, overexpressed enzymes, or target proteins. This constant sensing will assure that the nanorobots do not become activated in normal tissues and will be activated once target pathological conditions are detected and increase accuracy in targeting.

3.4.4. Target Recognition

When the nanorobots sense the presence of the right biomarker signatures, the robots can then do target recognition via a combination of sensing signals. This is used to ensure the abnormality of the tissue and to ensure that there is no activation of false activation. Before therapeutic action is initiated, the control module confirms the target according to predetermined threshold levels or logic logic.

3.4.5. Drug Release or Mechanical Action

After the target has been detected, the nanorobot then switches on its therapeutic module. This can include controlled delivery of a therapeutic cargo or mechanical operation which may be targeted local disruption of disease cells. The release is highly controlled to bring about maximum therapeutic effects and minimal harm to the adjacent healthy tissue.

3.4.6. Biodegradation or Retrieval

At the end of their task, nanorobots can be biodegraded into non-toxic wastes that can be safely metabolized or excreted by the body in instances where they cannot be retrieved with external control fields, or nanorobots can undergo recovery by applying external control fields. This last procedure is to assure long term safety and to prevent the foreign material that may be accumulating to amass in the body.

4. RESULTS AND DISCUSSION

4.1. Performance Metrics

Table 1: Performance Metrics

Parameter	Conventional Therapy (%)	Nanorobotic System (%)
Targeting Accuracy	40%	90%
Systemic Toxicity	80%	10%
Invasiveness	70%	5%
Treatment Efficiency	60%	95%



Fig 4 - Performance Metrics

4.1.1. Targeting Accuracy

Specificity of conventional therapy is quite poor with an average of 40 percent success given the fact that the stuff or treatment agent circulates all over the body through the blood circulation. This non-specificity of distribution is a cause of minimal accumulation of drugs at the pathological target. Comparatively, however, the nanorobotic system has a 90 percent higher targeting accuracy thanks to its capacity to maneuver actively, detects particular biomarkers and delivers therapy at the site of action. This precision enhances the results of treatment and minimizes the discharge of unintended action on normal tissues.

4.1.2. Systemic Toxicity

The traditional therapies tend to be very systemically toxic estimated to be about 80 percent because the therapeutics are exposed to diseased and normal cells. Widespread exposure impacts severely causing side effects and restricts the maximum amount of dosage. The nanorobotic system minimally affects the systemic toxicity to close to 10 percent as drugs are delivered to the target site,

ISSN: 3071-5628
PP: 01-14.

and minimally off-target interactions occur. Consequently, the administration of higher doses of treatment becomes safe, which increases overall performance of treatment.

4.1.3. Invasiveness

The conventional modes of treatment, such as surgery and some of the localized therapies, are very invasive with an invasiveness level of about 70 percent. The procedures are commonly incisive, have lengthy healing periods and have more possibilities of complications. By contrast, nanorobotics have minimal invasiveness as it is minimized to approximately 5 percent. By being injected intravenously and functioning within the body, nanorobots do not cause the patient to receive a large surgical procedure, which adds much value to improving both patient comfort and recovery.

4.1.4. Treatment Efficiency

Conventional therapy has moderate treatment efficiency of approximately 60, which is a result of drug loss, non-specific action, and lack of control of dynamics of release. The nanorobotics systems have a very high level of treatment effectiveness, nearly 95%, because of the precision of the targeted delivery, control of the drug release and the ability to react to the biologic environment in real-time. This increases efficiency resulting in faster therapeutic response, decreased duration of treatment and better clinical outcomes.

4.2. Therapeutic Outcomes

The recent experimental and preclinical works have shown that nanorobotic drug delivery systems have the potential to provide significant enhancement in the treatment outcomes as compared to the traditional treatment methods applied. Improved tumor regression is among the most significant advantages, and it can be explained by the fact that nanorobots can be selectively accumulated on the basis of the location and secret therapeutic agents in a local and slow manner. Nanorobots can be actively targeted to diseased tissues and based on tumor-specific biomarkers, achieving high intracellular drug concentrations in cancer cells, which will inhibit tumor growth more efficiently, and in most instances, tumor growth will be contracted faster. This localized delivery lowers the amount of drugs wasted and makes a larger percentage of the dose injected to be directed towards the therapeutic effect. Along with enhanced efficiency, nanorobotic systems cause significant decrease of side effects associated with the treatment. Standard chemotherapy and systemic drug delivery tend to expose normal tissues with toxic substances leading to undesirable side effects like immunosuppression, organ damage, and pain to the patient. Nanorobots can address these concerns by limiting the release of drugs in pathological regions instead of the whole body which reduces systemic toxicity and enhances patient response. Consequently, increased doses and/or repeated doses can be administered without safety overexistence and, therefore, makes long-term treatment even more effective. The other critical therapeutic benefit is increased uptake of the cells. Nanorobots are designed by functionalizing the surface and having dimensions in the nano order which helps them to interact with cell membranes efficiently and thus endocytosis. This enhances the cellular and subcellular absorption of drugs thus making sure that therapeutic agents are delivered to the appropriate target intracellular locations. Moreover, nanorobotic swarm systems

ISSN: 3071-5628
PP: 01-14.

are more resistant to physiological perturbations (like unsteady blood flow, immune-compatibility and random Brownian motion). Nanorobot swarms have shown the ability to operate dependably and consistently as well as be reliable even in the face of unit failure through cooperative behaviour and decentralised control, allowing them to behave therapeutically in complex living systems.

4.3. Challenges and Limitations

Although nanorobotic systems have a strong potential in medicine, there are quite a number of challenges and limitations that need to be overcome before it can be a viable practice in various hospitals. Activation of the immune system is one of the issues. In the case of foreign nanostructures being placed into the body they can be interpreted as a threat thereby causing an immune response which can either be inflammation, opsonization or be cleared up very rapidly by the macrophages. Such reactions have the potential to decrease the time taken in circulation, restrict the efficiency of targeting and may result in undesired effects. One of the active researched aspects that have been applied to address this problem is designing nanorobots using very biocompatible materials, stealth coatings, or biomimetic surfaces. Failure to provide power supply and communication on a nanoscale will be another major constraint. Since nanorobots are very small, the common batteries and communication devices cannot be used. They are instead forced to rely on external sources of energy like magnetic fields, ultrasound or chemical gradients which limit the range of operation and functionality. Demonstratively, real-time communication and control of large swarms of nanorobots is technically a challenging exercise particularly in deep or complex biologic setups where signal attenuation and noise is common. Mass production also poses more challenges. The production of nanorobots at a scale of an industrial scale in uniform size, functionality and reliability is technically complicated and expensive. The existing nanofabrication and self-assembly processes usually do not have the throughput and reproducibility necessary to achieve mass-manufacturing, and hence commercialization capability is limited. Lastly, the regulatory permissibility of nanorobotic therapies is undergoing development. Current medical equipment and pharmaceutical policies do not encompass the peculiarities of autonomous or semi-autonomous nanodevices at full extent. This would require extensive safety testing, in-vitro toxicity and obvious regulatory policies, which can slow down clinical translation significantly and raise the cost of the development.

5. CONCLUSION

Nanorobotics is a game changer in the contemporary medical field, and it has the potential of radically redesigning the process of disease diagnosis, monitoring, and treatment. Medical nanorobots open up opportunities that were initially unavailable to traditional therapy techniques because of their ability to perform specific, controlled, and minimally invasive therapies to the cellular and molecular level. Active navigation of complex biological conditions, disease-specific biomarker recognition, and targeted therapy are all responses of high accuracy that make nanorobotics a major enabling factor of precision medicine. The nanorobotic systems can substantially increase the effectiveness of treatment and decrease systemic toxicity and patient discomfort as recent experimental and preclinical studies demonstrated. Even with such promising benefits, current nanorobotic systems have been limited mostly to the experimental or proof-of-concept phase. Power supply, navigation, real-time control, and large-scale manufacturing have all been characterized by technical challenges which are limiting to immediate clinical deployment. Nevertheless, this gap is gradually being bridged by the rapid advances in making technologies available. Deploying technologies of nanofabrication, including DNA origami and self-assembly, have enhanced structural specificity and functional integration on a nanoscale scale. On the same note, advancements in artificial intelligence and machine learning are also being used to bring more intelligent control schemes, adaptive navigation, and strong swarm coordination to enable nanorobots to work more efficiently in dynamic physiological conditions. Biocompatibility and longer-term safety should be made the key focus in the future research in order to make sure that nanorobots can circulate, operate, and be clear out of the body without the development of harmful immune reactions or without accumulating in critical organs. As well is the development of quality real-time controls and imaging processes that enable clinicians to track the behavior and movement of nanorobots and act upon it notwithstanding. Ethical questions, such as patient consent, data privacy, and control over autonomous medical devices should also be taken into consideration in order to gain trust of the population and deploy the devices responsibly. Overall, the formulation of uniform regulatory stations specifically designed to nanorobotic systems is necessary to expedite clinical translation. Safety testing, performance analysis as well as post-treatment monitoring guidelines will be clear to provide a path to the approval processes and to induce investment in the industry. Through continued staunch interdisciplinary partnership between engineers, clinicians, biologists, ethicists, and policymakers, medical nanorobotics will be transformed into one of the enabling technologies of the next-generation healthcare and will form the foundation of personalized and precision medicine in the decade or so to come.

REFERENCES

[1] K. E. Drexler, *Engines of Creation: The Coming Era of Nanotechnology*, New York, NY, USA: Anchor Press/Doubleday, 1986.

[2] K. E. Drexler, *Nanosystems: Molecular Machinery, Manufacturing, and Computation*, New York, NY, USA: Wiley, 1992.

[3] R. A. Freitas Jr., "Current status of nanomedicine and medical nanorobotics," *J. Comput. Theor. Nanosci.*, vol. 2, no. 1, pp. 1–25, 2005.

[4] R. A. Freitas Jr., *Nanomedicine, Volume I: Basic Capabilities*, Georgetown, TX, USA: Landes Bioscience, 1999.

[5] D. Peer *et al.*, "Nanocarriers as an emerging platform for cancer therapy," *Nature Nanotechnology*, vol. 2, no. 12, pp. 751–760, 2007.

[6] T. M. Allen and P. R. Cullis, "Drug delivery systems: Entering the mainstream," *Science*, vol. 303, no. 5665, pp. 1818–1822, 2004.

[7] H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto, "Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications," *Int. Immunopharmacol.*, vol. 3, no. 3, pp. 319–328, 2003.

[8] S. M. Moghimi, A. C. Hunter, and J. C. Murray, "Long-circulating and target-specific nanoparticles: Theory to practice," *Pharmacol. Rev.*, vol. 53, no. 2, pp. 283–318, 2001.

[9] S. Douglas *et al.*, "A logic-gated nanorobot for targeted transport of molecular payloads," *Science*, vol. 335, no. 6070, pp. 831–834, 2012.

[10] P. W. K. Rothemund, "Folding DNA to create nanoscale shapes and patterns," *Nature*, vol. 440, no. 7082, pp. 297–302, 2006.

[11] M. Medina-Sánchez, O. G. Schmidt, and F. J. Schwarz, "Medical microbots: In vivo applications," *Advanced Drug Delivery Reviews*, vol. 95, pp. 2–17, 2015.

[12] J. Wang and W. Gao, "Nano/microscale motors: Biomedical opportunities and challenges," *ACS Nano*, vol. 6, no. 7, pp. 5745–5751, 2012.

[13] L. Zhang *et al.*, "Artificial bacterial flagella: Fabrication and magnetic control," *Applied Physics Letters*, vol. 94, no. 6, pp. 064107-1–064107-3, 2009.

[14] B. Jang, E. Gutman, N. Stucki, and B. J. Nelson, "Undulatory locomotion of magnetic nanorobots using a rotating magnetic field," *IEEE Robotics and Automation Letters*, vol. 3, no. 3, pp. 1–8, 2018.

[15] M. Rubenstein, A. Cornejo, and R. Nagpal, "Programmable self-assembly in a thousand-robot swarm," *Science*, vol. 345, no. 6198, pp. 795–799, 2014.